언어선택 ENG
전체메뉴

IMB-201

Innovative Medicines based on
ImmunoModulatory Biologics

IMB-201

IMB-201 is an immuno-oncology antibody drug candidate which binds to the novel immune checkpoint protein, HLA-G, expressed on the surface of the cancer cells. Initially known to play an important role in fetal immune tolerance, HLA-G has become an attractive target in cancer therapeutics. By expressing HLA-G, cancer cells can escape the immune system by suppressing the killing activity of immune cells (NK, CD8+ T cell, and macrophage). IMB-201 inhibits HLA-G to reactivate the immune system, enabling the attack on tumor cells.

좌우로 스크롤 하시면 전체 내용을 확인할 수 있습니다.

High efficacy

In the tumor microenvironment, the interaction of IMB-201 with cancer cells:
1) induces an innate immune response by activating macrophage phagocytosis and NK cell-mediated cytotoxicity, and
2) increases the cytotoxic effect of infiltrated CD8+ T cells.
Based on this MoA, we expect IMB-201 has the potential to perform faster with higher efficacy than existing immuno-oncology agents.

좌우로 스크롤 하시면 전체 내용을 확인할 수 있습니다.